We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fibroblast Growth Factor May Regulate Movement

By Biotechdaily staff writers
Posted on 24 Jul 2002
A study has found that fibroblast growth factor 14 (FGF14), which belongs to a distinct subclass of FGFs expressed in the developing and adult central nervous system, does not act like a growth factor. More...
Instead, it appears to have a functional role in the transmission of signals within the nervous system and may help regulate walking and movement. The research was reported in the July 3, 2002, issue of Neuron.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) developed a strain of mice containing a mutant gene for FGF14. The mutant gene coded for a modified FGF14 that contained a beta-galactosidase residue, which rendered the molecule nonfunctional.

Mice born with this mutation developed coordination problems and abnormal posture. Compared with normal mice they walked sluggishly and shuffled, and they had reduced muscle strength. They also were less sensitive to stimulants such as cocaine and amphetamines and were more prone to drug-induced seizures. When the researchers looked at brain tissue removed from the mutant mice for the location of beta-galactosidase, they found that the modified version of FGF14 was transported throughout the basal ganglia and cerebellum, areas in the brain related to motor function. Thus, FGF14 may be linked to movement disorders, such as Parkinson's and Huntington's diseases.

"We believe we have found a new signaling pathway in the brain,” said study leader Dr. David M. Ornitz, professor of molecular biology and pharmacology at Washington University. "Once we learn what FGF14 does at the molecular level, I believe we may uncover a new mechanism for regulating nerve cell function. It is pretty clear now that FGF14 is not a growth factor.”



Related Links:
Washington University School of Medicine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.